Company has consistently scaled their global manufacturing network to serve the rapidly growing life sciences market but still experienced an inability to reduce backorders and lead times. The company determined that the manufacturing of non-regulated lab scale cGMP products was negatively impacting their ability to meet customer demand across higher priority portfolio products.
Ultimately, the company decided to repurpose their existing manufacturing footprint for higher-value proprietary media products and custom manufacturing for end customers by outsourcing the manufacturing of certain lab-scale products.
GeminiBio collaborated with the company to document all product specifications and requirements to determine the most cost-effective manufacturing approach for over 50 different lab-scale non-proprietary medias and buffers.
GeminiBio manufactured pilot batches and completed a comprehensive audit process with the company to validate GeminiBio’s contract manufacturing service.
GeminiBio was able to manufacture 100-liter to 1,000-liter lots of product and package in 500 mL and 1-liter bottles in the company’s ISO 13485 and 21 CFR 820 compliant facility.
By outsourcing the manufacturing of selected non-proprietary medias and buffers, the company was able to continue to profitably offer these lab-scale products to end-customers while freeing up self-manufacturing capacity for higher value catalog products and end-customer custom media manufacturing.